PROBILIFT D Drops

6-Strain Probiotic + Vitamin D3

Probiotics are beneficial bacteria essential for improving intestinal health. The microflora of newborn babies is underdeveloped, making them more susceptible to opportunistic gut conditions1. ProbiLIFT D is a probiotic supplement specifically formulated with 6 probiotic strains and vitamin D.

By supplementing your baby’s diet with ProbiLIFT D, you can strengthen the barrier effect in the intestines to keep them healthy2. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria.

By introducing live probiotic cultures to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise within the intestines3. The addition of vitamin D may help with the development of healthy bones and teeth and may contribute to the normal function of the immune system.

What does ProbiLIFT D do?

  • Fights the growth of harmful bacteria

  • Supports the immune system

  • Assists in the development of healthy bones & teeth

ProbiLIFT D can replace the good bacteria lost through:

  • Antibiotic treatment4

  • Diarrhoea & Constipation5,6

  • GI infection3

  • Malnutrition

Probiotics can assist in:

  • Reducing the side effects of antibiotic treatment4

  • Minimising GI discomfort and bloating associated with IBS (irritable bowel syndrome), IBD (inflammatory bowel disease) & colitis (intestinal inflammation)9,10

  • Prevention and treatment of allergic skin reactions and eczema11

Why 6 strains?

The beneficial effects of probiotics are both strain- and dose-specific. A combination of various probiotic strains working together has been
shown to be the most effective in the gut7. In addition, more significant results can be achieved with multiple strains in combination compared to single strain preparations8.

How to Use:

If your baby is on antibiotics, increase the dose to 1 ml three times per day for the duration of the antibiotic course, and for 3 days after. Do not administer probiotics and antibiotics together. 

Preservative, sugar, flavouring and colourant free.

Do not exceed the recommended daily dosage.
Shake the bottle well before use.

Always tell your healthcare professional if you are taking other medicines on a regular basis, including complementary or traditional medicines. Safety for use during pregnancy and lactation has not been established.

Porphyria: Safety has not been established.
Do not use when known sensitivity or allergy exists towards any of the ingredients.

STORE OUT OF SIGHT AND REACH OF CHILDREN
This medicine has not been evaluated by the South African Health Product Regulatory Authority (SAHPRA) for its efficacy and intended use. This medicine is not intended to diagnose, treat, cure or prevent any disease.

DOSAGE AND DIRECTIONS FOR USE:
Children < 2 years 1 ml daily

INGREDIENTS:  Active substances per 1 ml:
1 billion CFU* probiotics consisting of a blend of:
Bifidobacterium lactis BI-07® 200 million CFU
Bifidobacterium longum BI-05® 150 million CFU
Lactobacillus acidophilus La-14® 200 million CFU
Lactobacillus reuteri 1E1 150 million CFU
Lactobacillus rhamnosus Lr-32® 150 million CFU
Lactobacillus salivarius Ls-33® 150 million CFU
Vitamin D3 (as cholecalciferol) 400 IU

*CFU – Colony Forming Units

Inactive Ingredients:
Medium Chain Triglyceride (MCT) oil and silicon dioxide.

Detailed Information:

Scheduling status: S0. Proprietary name (and dosage form): PROBILIFT D (capsules). Pharmacological classification: D. 34.12 Multiple Substance Formulation. Complementary Medicines. Health Supplement. Pharmacological action: Probiotics are beneficial bacteria, essential for improving intestinal health. Babies are born without any microflora and are thus more susceptible to opportunistic gut conditions. PROBILIFT D is a probiotic supplement specially formulated with 6 probiotic strains and vitamin D. By supplementing your baby’s diet with PROBILIFT D, you can strengthen the barrier effect in the intestines to keep them healthy. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise the intestine. The addition of vitamin D may help with the development of healthy bones and teeth and may contribute to the normal function of the immune system. PROBILIFT D has been specially formulated for babies. When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive tract. Identification: PROBILIFT D contains a cream coloured liquid with white suspended particles. Presentation PROBILIFT D is packed in a 30 ml amber glass bottle containing 30 ml of liquid, with a black plastic tamper evident cap and graduated glass pipette. Agera Health. info@agerapharma.co.za . www.agerahealth.co.za . 30 ml.

Resources:

  1. Binns, N. (2013) Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monograph Series.
  2. Lutgendorff, F., Akkermans, L. M., Söderholm, J. D. (2008). The role of microbiota and probiotics in stress-induced gastrointestinal damage. Current Molecular Medicine, 8, 282-98.
  3. Fooks, L. J., Fuller, R., Gibson, G. R. (1999). Prebiotics, probiotics and human gut microbiology. International Dairy Journal, 9, 53-61.
  4. Kyne, L., Kelly, C. P. (2001). Recurrent Clostridium difficile diarrhoea. Gut, 49, 152–153.
  5. Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S, Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. The Lancet Infectious Diseases, 6(6), 374 –382.
  6. Guandalini, S. (2006). Probiotics for children: use in diarrhea. Journal of Clinical Gastroenterology, 40(3), 244–248.
  7. Timmerman, H. M., Koning, C. J., Mulder, L., Rombouts, F. M., Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. International Journal of Food Microbiology, 96(3), 219-233.
  8. Leyer, G. J., Li, S., Mubasher, M. E., Reifer, C., Arthur C. Ouwehand, A. C. (2009). Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics, 124, 172-179.
  9. Ringel, Y., Ringel-Kulka, T., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., Palsson, O. S. (2011). Clinical trial: Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders – a Double-Blind Study. Journal of Clinical Gastroenterology, 45(6), 518–525.
  10. Van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L., Bienenstock, J. (2008). Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology- Regulatory, Integrative & Comparative Physiology, 295, 1131–1137.
  11. Rautava, S., Kalliomaki, M., Isolauri, E. (2005). New therapeutic strategy for combating the increasing burden of allergic disease: probiotics: a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy & Clinical Immunology, 116(1), 31–37.